Central Lab Market Size Forecast To Achieve $4.82 Billion By 2030 With 7.8% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Central Lab Market Become By 2030 Compared To 2026?

The central nervous system (cns) lymphoma market size has seen substantial growth in recent years. It is projected to increase from $1.53 billion in 2025 to $1.63 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.6%. This historical expansion can be attributed to several factors, including enhanced accuracy in lymphoma diagnostic methods, the greater utilization of high-dose chemotherapy protocols, the expansion of hospital oncology infrastructure, advancements in neuro-oncology research, and the growing accessibility of corticosteroid therapies.

The central nervous system (cns) lymphoma market size is anticipated to experience substantial growth in the upcoming years. It is forecast to expand to $2.09 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.4%. This expansion during the forecast period can be attributed to several factors such as increased investments in targeted oncology drugs, the growing acceptance of personalized cancer treatment, the broadening of biomarker-driven therapy selection, a heightened focus on rare cancer research, and intensified clinical trial activity in cns malignancies. Prominent trends expected over this period include the rising adoption of targeted immunotherapy treatments, an increase in the use of monoclonal antibody-based therapies, the expanding integration of precision diagnostics into treatment planning, the development of combination therapy approaches, and an enhanced emphasis on early disease detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7317&type=smp

Which Drivers Are Advancing The Central Lab Market Growth?

The Central Nervous System (CNS) lymphoma market is projected to expand due to the growing number of psychological disorders. These conditions are defined as mental health issues that interfere with an individual’s thoughts, feelings, or actions, leading to suffering or functional difficulties. Factors such as stress, social isolation, financial strain, genetic predispositions, substance misuse, and excessive digital engagement contribute to the increase in psychological disorders. Research into Central Nervous System (CNS) lymphoma promotes advancements in neuro-oncology, enhancing insights into brain inflammation, immune system interactions, and the blood-brain barrier, which in turn facilitates the development of improved therapies for both cancer and mental health conditions. For example, the National Health Service, a UK government body, reported in November 2023 that an estimated one in five individuals between 8 and 25 years old had a probable mental disorder in 2023, impacting 20.3% of 8 to 16-year-olds, 23.3% of 17 to 19-year-olds, and 21.7% of 20 to 25-year-olds. Consequently, the rising occurrence of psychological disorders is driving demand within the Central Nervous System (CNS) lymphoma market.

How Is The Central Lab Market Distributed Across Key Segments?

The central lab market covered in this report is segmented –

1) By Service Type: Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology Or Histology, Specimen Management And Storage, Special Chemistry Services, Other Service Types

2) By Test Type: Human And Tumor Genetics, Clinical Chemistry, Medical Microbiology And Cytology, Other Esoteric Tests

3) By End-User: Pharmaceutical Companies, Academic And Research Institutes, Biotechnology Companies

Subsegments:

1) By Genetic Services: DNA Sequencing, Genotyping, Gene Expression Analysis

2) By Biomarker Services: Biomarker Discovery, Biomarker Validation, Pharmacodynamic Biomarker Testing

3) By Microbiology Services: Bacterial Identification And Susceptibility Testing, Virology Testing, Mycology And Parasitology Testing

4) By Anatomic Pathology Or Histology: Tissue Sample Analysis, Immunohistochemistry (IHC), Slide Preparation and Staining

5) By Specimen Management And Storage: Biorepository Services, Sample Collection And Handling, Long-Term Sample Storage

6) By Special Chemistry Services: Toxicology Testing, Metabolomics, Hormonal Assays

7) By Other Service Types: Hematology Testing, Coagulation Testing, Flow Cytometry Services

Which Trends Are Contributing To Changes In The Central Lab Market?

Leading companies operating within the central nervous system (CNS) lymphoma market are concentrating on developing innovative therapies, such as Tirabrutinib, for the treatment of primary central nervous system (CNS) lymphoma. Tirabrutinib functions as a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, engineered to treat B-cell malignancies, including primary central nervous system lymphoma (PCNSL), by impacting pathways vital for cancer cell endurance and growth. For instance, in March 2023, ONO Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had designated tirabrutinib (ONO-4059) as an orphan drug for primary central nervous system lymphoma (PCNSL). This compound, currently being evaluated in the phase 2 PROSPECT study (NCT04947319), is a potent and selective BTK inhibitor that specifically targets B-cell proliferation and survival. Tirabrutinib modulates cellular proliferation and activation via the B-cell receptor, thereby facilitating the survival, differentiation, and clonal expansion of B-cells.

Which Key Players Are Active In The Central Lab Market?

Major companies operating in the central lab market are Celerion Inc., Cerba Research, Cirion Biopharma Research Inc., Clinical Reference Laboratory Inc., Eurofins Central Laboratory LLC, Frontage Laboratories Inc., Interlab Central Lab Services, InVitro International, LabConnect LLC, Labcorp Drug Development India Private Limited, Medpace Clinical Research India Private Limited, MLM Medical Labs GmbH, Q2 Solutions Pty Ltd., Sonic Healthcare Limited, Synevo Central Lab, Acm Global Laboratories Private Limited, Altasciences, Barc Lab, BioIVT LLC, ICON plc, Intertek, LabNow LLC, Medidata Solutions, NAMSA LLC, Neoteryx, Northwell Health Labs, PAREXEL International, Pharm-Olam LLC, Pharmaceutical Product Development, PRA Health Sciences, Quest Diagnostics, IQVIA Co., Rho Inc.

Access The Complete Central Lab Market Report:

https://www.thebusinessresearchcompany.com/report/central-lab-global-market-report

Which Region Is The Dominant Market In The Central Lab Market?

North America was the largest region in the central lab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central lab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Central Lab Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=7317&type=smp

Browse Through More Reports Similar to the Global Central Lab Market 2026, By The Business Research Company

Pharmacy Automation Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-automation-global-market-report

Pharmacy Automation Solution Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-automation-solution-global-market-report

Pharmacy Automation Systems Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-automation-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795